Menu
← Oncology Approval Tracker
FDA DECISION ·
Tecvayli
teclistamab-cqyv · Janssen Biotech
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with relapsed or refractory multiple myeloma after at least four lines, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody.
LAMPGEN ANALYSIS
Why it matters
The initial indication brings a BCMA-directed bispecific T-cell engager to a heavily pretreated myeloma population.
What research teams should watch
Reconstruct therapy history and coordinate step-up dosing, infection monitoring, and escalation for cytokine release syndrome.
PRIMARY RECORDS